Larimar Therapeutics Inc Stock Price, News & Analysis

Larimar Therapeutics (Nasdaq: LRMR), a clinical-stage biotech company, has successfully closed its previously announced underwritten public offering. The company sold 21,562,500 shares of common stock at $3.20 per share, including the full exercise of the underwriters' option to purchase 2,812,500 additional shares.

The offering generated gross proceeds of $69.0 million, which will be used to support the development of nomlabofusp and other pipeline candidates, working capital, and general corporate purposes including R&D and pre-commercialization expenses. The offering was managed by joint bookrunners Leerink Partners, Guggenheim Securities, Truist Securities, and William Blair.

Larimar Therapeutics (NASDAQ: LRMR), a clinical-stage biotech company, has announced the pricing of its underwritten public offering of 18.75 million shares of common stock at $3.20 per share. The offering is expected to generate $60 million in gross proceeds before deducting expenses.

The company has granted underwriters a 30-day option to purchase up to an additional 2.81 million shares. The offering, expected to close around July 31, 2025, is being managed by Leerink Partners, Guggenheim Securities, Truist Securities, and William Blair. Proceeds will support the development of nomlabofusp, other pipeline candidates, and general corporate purposes including R&D and pre-commercialization expenses.

Larimar Therapeutics (NASDAQ: LRMR), a clinical-stage biotech company, has announced a proposed underwritten public offering of its common stock and pre-funded warrants. The offering includes a 30-day option for underwriters to purchase up to an additional 15% of securities at the public offering price.

The company plans to use the proceeds to support the development of nomlabofusp and other pipeline candidates, along with working capital and general corporate purposes. Leerink Partners and Guggenheim Securities are serving as joint bookrunning managers for the offering, which will be made under an effective S-3 shelf registration.

Larimar Therapeutics (NASDAQ:LRMR) has published two peer-reviewed articles highlighting nonclinical data supporting nomlabofusp as a potential treatment for Friedreich's ataxia (FA). The research demonstrates the drug's mechanism of action and its ability to increase frataxin (FXN) protein levels in key tissues.

The data was included in the FDA briefing package supporting the use of skin FXN concentrations as a reasonably likely surrogate endpoint for accelerated approval. Larimar plans to submit a Biologics License Application (BLA) in Q2 2026, positioning nomlabofusp as the first potential disease-modifying therapy for FA patients.

Larimar Therapeutics (LRMR) has received FDA recommendations for its nomlabofusp Biologics License Application (BLA) for treating Friedreich's Ataxia. The FDA recommends a safety database of at least 30 participants with 6-month continuous exposure and 10 participants with 1-year exposure, primarily at the 50 mg dose. The company plans to submit its BLA in Q2 2026, seeking accelerated approval. The FDA is open to using skin frataxin concentrations as a reasonably likely surrogate endpoint. Larimar expects to report data from 30-40 participants in their open-label extension study and adolescent PK run-in data in September 2025. The company is advancing its global Phase 3 study with sites in multiple countries, which will serve as the confirmatory study for accelerated approval.

Larimar Therapeutics (NASDAQ: LRMR), a clinical-stage biotech company specializing in rare disease treatments, has scheduled a conference call and webcast for June 23, 2025, at 8:00 am EDT. The purpose of the call is to provide regulatory updates regarding their nomlabofusp clinical development program for Friedreich's Ataxia treatment. Participants can join via webcast or by dialing 1-877-407-9716 (domestic) or 1-201-493-6779 (international) with conference ID 13754491. An archived version of the webcast will be available on Larimar's website after the live event.

Larimar Therapeutics reported Q1 2025 financial results with significant progress in their nomlabofusp clinical development program for Friedreich's Ataxia (FA). The FDA has shown openness to considering skin FXN concentration as a surrogate endpoint for accelerated approval, with a BLA submission planned for year-end 2025.

Key developments include completion of adolescent dosing in the PK run-in study, plans for a global Phase 3 study in mid-2025, and an upcoming program update in September 2025 featuring OLE study data. The company maintains a strong financial position with $157.5 million in cash and equivalents, providing runway into Q2 2026.

Financial highlights show a Q1 2025 net loss of $29.3 million ($0.46 per share), compared to $14.7 million in Q1 2024. R&D expenses increased to $26.6 million, while G&A expenses rose to $4.6 million. The company is advancing toward potential registration of the first disease-modifying therapy for FA patients.

Larimar Therapeutics (NASDAQ: LRMR) has reported significant progress in its nomlabofusp development program for Friedreich's ataxia (FA). The FDA has indicated openness to considering skin frataxin (FXN) concentration as a surrogate endpoint for accelerated approval, acknowledging data supporting the relationship between skin FXN and relevant tissues.

Key developments include:

• BLA submission targeted for year-end 2025
• Global Phase 3 study planned for mid-2025
• Open Label Extension study progressing with 50mg dose
• Pediatric PK run-in study advancing for adolescents

Financial highlights:

• Q4 2024 net loss of $28.8 million ($0.45 per share)
• Full year 2024 net loss of $80.6 million ($1.32 per share)
• Strong cash position of $183.5 million as of December 31, 2024
• Cash runway projected into Q2 2026

Larimar Therapeutics (Nasdaq: LRMR), a clinical-stage biotechnology company specializing in complex rare disease treatments, has announced its participation in the upcoming Leerink Partners Global Healthcare Conference in Miami Beach, FL.

The company's management team will deliver a presentation on Monday, March 10, 2025, from 3:40 to 4:10 PM EST and engage in one-on-one investor meetings throughout the conference, which runs from March 10-12, 2025. The presentation will be accessible via webcast, and a replay will remain available for 30 days on Larimar's website under the 'Events and Presentations' section.